-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint inflammation, which can lead to joint damage and impaired body function.
Rheumatoid Arthritis Immunity Recently, researchers have investigated the effect of gradual reduction of csDMARDs on the risk of relapse in RA patients who have achieved sustained remission compared with continued maintenance treatment.
ARCTIC REWIND is a multi-center, randomized, parallel, open non-inferiority study carried out in 10 hospitals in Norway.
The average age of the patients was 55.
In the csDMARD dose halved group, 19 patients (25%) had relapses, while the csDMARD dose stabilized group had only 5 patients (6%).
Studies believe that for patients with rheumatoid arthritis who have received traditional synthetic anti-rheumatic drugs to improve their condition, the risk of recurrence increases after the drug dose is reduced by half during the maintenance treatment period.
For patients with rheumatoid arthritis who received traditional synthetic anti-rheumatic drugs and their condition was relieved, the risk of recurrence increased after the drug dose was reduced by half during the maintenance treatment period.
Original source
Siri Lillegraven et al.
com/journals/jama/article-abstract/2779548" target="_blank" rel="noopener">Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission The ARCTIC REWIND Randomized Clinical Trial Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease in Patients With Rheumatoid Arthritis Flares in Remission at the ARCTIC REWIND Randomized Clinical Trial JAMA
in this message